Little Green Pharma (LGP) has landed its first shipment of medicinal cannabis flower in Australia from its recently acquired facility in Denmark.

The shipment includes 50kg of “THC 16 — Billy Buttons”, named after the eponymous Australian wildflower. The flower has a THC content of 16% and is available on the Australian market in 15g packs. 

Little Green Pharma managing director Fleta Solomon

The company anticipates a further two shipments of cannabis flower medicines totalling 65kgs will arrive from the facility by the end of October 2021 to meet the growing demand for dried cannabis flower in Australia.

LGP managing director Fleta Solomon said: “Flower medicines are becoming increasingly popular with Australian doctors in prescribing to patients for quick onset of effects, mainly for breakthrough pain or to assist with sleep, and with access to this Denmark-grown product we are able to provide a new supply chain of high-quality medicinal cannabis flower in an under-supplied market.

 “The import of this first shipment so quickly following the acquisition is a milestone achievement by our new Denmark team. 

“To be able to meet all the regulatory requirements to supply and import product within this timeframe is a significant achievement.” 

LGP’s Billy Buttons medicine is grown under Good Agricultural and Collection Practices (GACP) and is TGA and EU Good Manufacturing Practices (EU GMP) compliant. 

Meanwhile, LGP has appointed former managing director of the Danish facility Morten Snede as CFO and former managing director of Tasmanian Botanics Tony Roberts as general manager (EU).

Solomon said both new recruits bring a huge amount of expertise to LGP, having “overseen the creation and development of significant medicinal cannabis businesses in their own right”.